Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.
AuthorWhite, Judith M
Schiffer, Joshua T
Bender Ignacio, Rachel A
Olinger, Gene G
Polyak, Stephen J
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractThe world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term with pairs of drugs in advanced clinical testing or repurposed agents approved for other indications. While significant efforts were launched against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in vitro and in the clinic, many studies employed solo drugs and had disappointing results. Here, we review drug combination studies against SARS-CoV-2 and other viruses and introduce a model-driven approach to assess drug pairs with the highest likelihood of clinical efficacy. Where component agents lack sufficient potency, we advocate for synergistic combinations to achieve therapeutic levels. We also discuss issues that stymied therapeutic progress against COVID-19, including testing of agents with low likelihood of efficacy late in clinical disease and lack of focus on developing virologic surrogate endpoints. There is a need to expedite efficient clinical trials testing drug combinations that could be taken at home by recently infected individuals and exposed contacts as early as possible during the next pandemic, whether caused by a coronavirus or another viral pathogen. The approach herein represents a proactive plan for global viral pandemic preparedness.
category A-C pathogens
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17593
- Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
- Authors: Artese A, Svicher V, Costa G, Salpini R, Di Maio VC, Alkhatib M, Ambrosio FA, Santoro MM, Assaraf YG, Alcaro S, Ceccherini-Silberstein F
- Issue date: 2020 Dec
- Drug Discovery Strategies for SARS-CoV-2.
- Authors: Shyr ZA, Gorshkov K, Chen CZ, Zheng W
- Issue date: 2020 Oct
- Remdesivir against COVID-19 and Other Viral Diseases.
- Authors: Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J
- Issue date: 2020 Dec 16
- Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
- Authors: Lisi L, Lacal PM, Barbaccia ML, Graziani G
- Issue date: 2020 Oct
- Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
- Authors: Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, Kim EJ, Casel MAB, Rollon R, Jang SG, Lee MH, Chang JH, Song MS, Jeong HW, Choi Y, Chen W, Shin WJ, Jung JU, Choi YK
- Issue date: 2020 May 22